JP2015506982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506982A5 JP2015506982A5 JP2014556739A JP2014556739A JP2015506982A5 JP 2015506982 A5 JP2015506982 A5 JP 2015506982A5 JP 2014556739 A JP2014556739 A JP 2014556739A JP 2014556739 A JP2014556739 A JP 2014556739A JP 2015506982 A5 JP2015506982 A5 JP 2015506982A5
- Authority
- JP
- Japan
- Prior art keywords
- acetamide
- oxy
- methoxy
- hydrogen
- dimethyltetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- -1 scan Rufaniru Chemical group 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000002837 carbocyclic group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- WCMDBIBPDWXHLO-PZKXETHGSA-N n-[2-[2-(3-chlorophenyl)-4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxyphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(Cl)C=CC=2)=C1 WCMDBIBPDWXHLO-PZKXETHGSA-N 0.000 claims 6
- PDBWOHBMJQOBHL-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-fluorophenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(F)C=CC=2)=C1 PDBWOHBMJQOBHL-PZKXETHGSA-N 0.000 claims 6
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
- SGCBVAURWZNEQM-PZKXETHGSA-N n-[2-[2-(2-chlorophenyl)-4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxyphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C(=CC=CC=2)Cl)=C1 SGCBVAURWZNEQM-PZKXETHGSA-N 0.000 claims 4
- FYOSKKALYXICAT-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(4-fluorophenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=CC(F)=CC=2)=C1 FYOSKKALYXICAT-PZKXETHGSA-N 0.000 claims 4
- KQQHONCNKVGSRS-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-[3-(trifluoromethyl)phenyl]phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(C=CC=2)C(F)(F)F)=C1 KQQHONCNKVGSRS-PZKXETHGSA-N 0.000 claims 4
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- GASFVSRUEBGMDI-UHFFFAOYSA-N n-aminohydroxylamine Chemical compound NNO GASFVSRUEBGMDI-UHFFFAOYSA-N 0.000 claims 3
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 2
- FEKRHVNJCYAFDY-DVZSQSHLSA-N n-[2-[2-(1,3-benzodioxol-5-yl)-4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxyphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C3OCOC3=CC=2)=C1 FEKRHVNJCYAFDY-DVZSQSHLSA-N 0.000 claims 2
- FHVBDUFGQZGTAB-UHFFFAOYSA-N n-[2-[2-(3-fluorophenyl)-4-(4-phenylmethoxycyclohex-2-en-1-yl)oxyphenyl]ethyl]acetamide Chemical compound C1=C(C=2C=C(F)C=CC=2)C(CCNC(=O)C)=CC=C1OC(C=C1)CCC1OCC1=CC=CC=C1 FHVBDUFGQZGTAB-UHFFFAOYSA-N 0.000 claims 2
- VBMJHAAMTRDGAN-UHFFFAOYSA-N n-[2-[2-(3-fluorophenyl)-4-(4-phenylmethoxycyclohexyl)oxyphenyl]ethyl]acetamide Chemical compound C1=C(C=2C=C(F)C=CC=2)C(CCNC(=O)C)=CC=C1OC(CC1)CCC1OCC1=CC=CC=C1 VBMJHAAMTRDGAN-UHFFFAOYSA-N 0.000 claims 2
- XAWGNQVOGSWZJO-UHFFFAOYSA-N n-[2-[2-(3-fluorophenyl)-4-(4-piperidin-4-ylcyclohexyl)oxyphenyl]ethyl]acetamide Chemical compound C1=C(C=2C=C(F)C=CC=2)C(CCNC(=O)C)=CC=C1OC(CC1)CCC1C1CCNCC1 XAWGNQVOGSWZJO-UHFFFAOYSA-N 0.000 claims 2
- LOGWBHYAVRGPRK-UHFFFAOYSA-N n-[2-[4-(4-tert-butylcyclohexyl)oxy-2-(3-fluorophenyl)phenyl]ethyl]acetamide Chemical compound C1=C(C=2C=C(F)C=CC=2)C(CCNC(=O)C)=CC=C1OC1CCC(C(C)(C)C)CC1 LOGWBHYAVRGPRK-UHFFFAOYSA-N 0.000 claims 2
- USRKXLZYHVZAKQ-DVZSQSHLSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(2-methylsulfanylphenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C(=CC=CC=2)SC)=C1 USRKXLZYHVZAKQ-DVZSQSHLSA-N 0.000 claims 2
- IWCBQOJUYYCSJR-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-fluorophenyl)-3-hydroxyphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(F)C=CC=2)=C1O IWCBQOJUYYCSJR-PZKXETHGSA-N 0.000 claims 2
- WURCPMKAUHZJSG-DVZSQSHLSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-fluorophenyl)-6-methoxyphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC(OC)=C(CCNC(C)=O)C(C=2C=C(F)C=CC=2)=C1 WURCPMKAUHZJSG-DVZSQSHLSA-N 0.000 claims 2
- YTOMKFORSOOKCK-DVZSQSHLSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-methoxyphenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(OC)C=CC=2)=C1 YTOMKFORSOOKCK-DVZSQSHLSA-N 0.000 claims 2
- VJJCASHYKLQLOQ-DVZSQSHLSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-methylphenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(C)C=CC=2)=C1 VJJCASHYKLQLOQ-DVZSQSHLSA-N 0.000 claims 2
- ZNFJDFYHYQOOEY-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-phenylphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=CC=CC=2)=C1 ZNFJDFYHYQOOEY-PZKXETHGSA-N 0.000 claims 2
- UZCUPBRWTVBHAZ-DJQAVYROSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-pyridin-3-ylphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=NC=CC=2)=C1 UZCUPBRWTVBHAZ-DJQAVYROSA-N 0.000 claims 2
- VMQCJCYASMOABW-DJQAVYROSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-pyridin-4-ylphenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=CN=CC=2)=C1 VMQCJCYASMOABW-DJQAVYROSA-N 0.000 claims 2
- BACNANPWQSGDKW-WJTHNMLFSA-N n-[6-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(3-fluorophenyl)phenyl]cyclohex-3-en-1-yl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC(C=C1C=2C=C(F)C=CC=2)=CC=C1C1C(NC(C)=O)CC=CC1 BACNANPWQSGDKW-WJTHNMLFSA-N 0.000 claims 2
- CWFDMFDEOABHBQ-WJTHNMLFSA-N n-[6-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-[3-(trifluoromethyl)phenyl]phenyl]cyclohex-3-en-1-yl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC(C=C1C=2C=C(C=CC=2)C(F)(F)F)=CC=C1C1C(NC(C)=O)CC=CC1 CWFDMFDEOABHBQ-WJTHNMLFSA-N 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- CEYAGQDUMVUARC-UHFFFAOYSA-N n-[2-[4-(2,3-dihydroxy-4-phenylmethoxycyclohexyl)oxy-2-(3-fluorophenyl)phenyl]ethyl]acetamide Chemical compound C1=C(C=2C=C(F)C=CC=2)C(CCNC(=O)C)=CC=C1OC(C(C1O)O)CCC1OCC1=CC=CC=C1 CEYAGQDUMVUARC-UHFFFAOYSA-N 0.000 claims 1
- SKZZDVRIEUKLDA-DVZSQSHLSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(2-methoxyphenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C(=CC=CC=2)OC)=C1 SKZZDVRIEUKLDA-DVZSQSHLSA-N 0.000 claims 1
- MUEUXVPQEBLPOJ-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-(4-hydroxyphenyl)phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=CC(O)=CC=2)=C1 MUEUXVPQEBLPOJ-PZKXETHGSA-N 0.000 claims 1
- NRGDXBNBAGJDQD-JRVZRWKPSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-[3-(morpholin-4-ylmethyl)phenyl]phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=C(CN3CCOCC3)C=CC=2)=C1 NRGDXBNBAGJDQD-JRVZRWKPSA-N 0.000 claims 1
- HDUVLBDYAALXGE-PZKXETHGSA-N n-[2-[4-[(3r,4s,5r)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-[4-(trifluoromethyl)phenyl]phenyl]ethyl]acetamide Chemical compound O1C(C)(C)[C@H](OC)[C@@H](O)[C@@H](O)C1OC1=CC=C(CCNC(C)=O)C(C=2C=CC(=CC=2)C(F)(F)F)=C1 HDUVLBDYAALXGE-PZKXETHGSA-N 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
- 0 CC(C)([C@@]([C@]([C@@]1O)O)OC)O[C@]1Oc1c(C)c(*)c(CCNC(C)=O)c(-c2c(*)c(*)*(*)*c2)c1* Chemical compound CC(C)([C@@]([C@]([C@@]1O)O)OC)O[C@]1Oc1c(C)c(*)c(CCNC(C)=O)c(-c2c(*)c(*)*(*)*c2)c1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597004P | 2012-02-09 | 2012-02-09 | |
| US61/597,004 | 2012-02-09 | ||
| PCT/US2013/025387 WO2013119985A1 (en) | 2012-02-09 | 2013-02-08 | C-terminal hsp90 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506982A JP2015506982A (ja) | 2015-03-05 |
| JP2015506982A5 true JP2015506982A5 (enExample) | 2016-03-17 |
| JP6121450B2 JP6121450B2 (ja) | 2017-04-26 |
Family
ID=47754998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556739A Active JP6121450B2 (ja) | 2012-02-09 | 2013-02-08 | Ｃ末端Ｈｓｐ９０阻害剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9422320B2 (enExample) |
| EP (3) | EP2812341B1 (enExample) |
| JP (1) | JP6121450B2 (enExample) |
| KR (1) | KR102124109B1 (enExample) |
| CN (2) | CN104271587B (enExample) |
| AU (1) | AU2013216858C1 (enExample) |
| BR (1) | BR112014019704B1 (enExample) |
| CA (1) | CA2866814C (enExample) |
| CY (1) | CY1122358T1 (enExample) |
| DK (2) | DK3656758T3 (enExample) |
| EA (1) | EA027147B1 (enExample) |
| ES (2) | ES2974721T3 (enExample) |
| FI (1) | FI3656758T3 (enExample) |
| HR (2) | HRP20191940T1 (enExample) |
| HU (2) | HUE046939T2 (enExample) |
| LT (2) | LT3656758T (enExample) |
| MX (1) | MX361233B (enExample) |
| NZ (1) | NZ629778A (enExample) |
| PL (2) | PL3656758T3 (enExample) |
| PT (2) | PT3656758T (enExample) |
| RS (2) | RS59719B1 (enExample) |
| SI (2) | SI3656758T1 (enExample) |
| SM (2) | SMT201900660T1 (enExample) |
| WO (1) | WO2013119985A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104271587B (zh) | 2012-02-09 | 2017-09-12 | 堪萨斯大学 | Hsp90C端抑制剂 |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| CA3289739A1 (en) * | 2014-06-24 | 2025-11-29 | The Univ Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| WO2016145219A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Treatment of peripheral neuropathies |
| CN111479815A (zh) * | 2017-12-20 | 2020-07-31 | 默克专利有限公司 | 杂芳族化合物 |
| IL276583B2 (en) * | 2018-02-07 | 2025-03-01 | Reata Pharmaceuticals Inc | Crystal structures of proline and a novobiocin analog |
| US11827664B2 (en) * | 2018-05-14 | 2023-11-28 | Reata Pharmaceuticals, Inc | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| AU2005301957B2 (en) | 2004-11-03 | 2012-02-23 | Department Of Health And Human Services | Novobiocin analogues as anticancer agents |
| US8846742B2 (en) * | 2006-02-14 | 2014-09-30 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CA2669687C (en) | 2006-11-15 | 2013-09-10 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| MX2009009936A (es) | 2007-03-20 | 2010-02-11 | Curis Inc | Amino piridina fusionada como inhibidores de hsp90. |
| US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5766617B2 (ja) * | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| EP2594554A4 (en) | 2010-07-13 | 2014-01-15 | Dainippon Sumitomo Pharma Co | BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS |
| CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| CN104271587B (zh) | 2012-02-09 | 2017-09-12 | 堪萨斯大学 | Hsp90C端抑制剂 |
| EP3066072B1 (en) | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
| WO2015070238A2 (en) | 2013-11-11 | 2015-05-14 | The University Of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The Univ Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| US11827664B2 (en) | 2018-05-14 | 2023-11-28 | Reata Pharmaceuticals, Inc | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
-
2013
- 2013-02-08 CN CN201380019057.XA patent/CN104271587B/zh active Active
- 2013-02-08 US US14/377,616 patent/US9422320B2/en active Active
- 2013-02-08 KR KR1020147025348A patent/KR102124109B1/ko active Active
- 2013-02-08 PL PL19193576.6T patent/PL3656758T3/pl unknown
- 2013-02-08 EP EP13706822.7A patent/EP2812341B1/en active Active
- 2013-02-08 CN CN201710729038.6A patent/CN107474085B/zh active Active
- 2013-02-08 WO PCT/US2013/025387 patent/WO2013119985A1/en not_active Ceased
- 2013-02-08 LT LTEP19193576.6T patent/LT3656758T/lt unknown
- 2013-02-08 SM SM20190660T patent/SMT201900660T1/it unknown
- 2013-02-08 HR HRP20191940TT patent/HRP20191940T1/hr unknown
- 2013-02-08 SM SM20240145T patent/SMT202400145T1/it unknown
- 2013-02-08 HU HUE13706822A patent/HUE046939T2/hu unknown
- 2013-02-08 ES ES19193576T patent/ES2974721T3/es active Active
- 2013-02-08 BR BR112014019704-0A patent/BR112014019704B1/pt active IP Right Grant
- 2013-02-08 EA EA201491496A patent/EA027147B1/ru unknown
- 2013-02-08 HU HUE19193576A patent/HUE066259T2/hu unknown
- 2013-02-08 SI SI201332079T patent/SI3656758T1/sl unknown
- 2013-02-08 CA CA2866814A patent/CA2866814C/en active Active
- 2013-02-08 EP EP19193576.6A patent/EP3656758B1/en active Active
- 2013-02-08 AU AU2013216858A patent/AU2013216858C1/en active Active
- 2013-02-08 SI SI201331622T patent/SI2812341T1/sl unknown
- 2013-02-08 NZ NZ629778A patent/NZ629778A/en unknown
- 2013-02-08 PL PL13706822T patent/PL2812341T3/pl unknown
- 2013-02-08 LT LT13706822T patent/LT2812341T/lt unknown
- 2013-02-08 FI FIEP19193576.6T patent/FI3656758T3/fi active
- 2013-02-08 MX MX2014009608A patent/MX361233B/es active IP Right Grant
- 2013-02-08 HR HRP20240514TT patent/HRP20240514T1/hr unknown
- 2013-02-08 RS RS20191454A patent/RS59719B1/sr unknown
- 2013-02-08 DK DK19193576.6T patent/DK3656758T3/da active
- 2013-02-08 ES ES13706822T patent/ES2755093T3/es active Active
- 2013-02-08 PT PT191935766T patent/PT3656758T/pt unknown
- 2013-02-08 DK DK13706822T patent/DK2812341T3/da active
- 2013-02-08 JP JP2014556739A patent/JP6121450B2/ja active Active
- 2013-02-08 PT PT137068227T patent/PT2812341T/pt unknown
- 2013-02-08 RS RS20240452A patent/RS65412B1/sr unknown
- 2013-02-08 EP EP24161059.1A patent/EP4403552A3/en active Pending
-
2016
- 2016-08-03 US US15/227,230 patent/US10030041B2/en active Active
-
2018
- 2018-06-26 US US16/018,401 patent/US10590157B2/en active Active
-
2019
- 2019-11-11 CY CY20191101180T patent/CY1122358T1/el unknown
-
2020
- 2020-02-05 US US16/783,025 patent/US10882881B2/en active Active
- 2020-12-04 US US17/112,060 patent/US11390640B2/en active Active
-
2022
- 2022-07-12 US US17/863,135 patent/US12024536B2/en active Active
-
2024
- 2024-05-17 US US18/667,496 patent/US20240417419A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506982A5 (enExample) | ||
| HRP20191940T1 (hr) | Inhibitori c-terminalnog hsp90 | |
| JP2015509535A5 (enExample) | ||
| RU2013144215A (ru) | Средство для борьбы с эндопаразитами | |
| CA2672652A1 (en) | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | |
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| JP2018515492A5 (enExample) | ||
| JP2015509534A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| JP2015516420A5 (enExample) | ||
| RU2010126056A (ru) | Органические соединения | |
| JP2020527175A5 (enExample) | ||
| RU2004126936A (ru) | Производные хинолина в качестве антагонистов npv | |
| JP2015536974A5 (enExample) | ||
| RU2015143675A (ru) | Ship1 модуляторы и относящиеся к ним способы | |
| JP2017505293A5 (enExample) | ||
| RU2007118727A (ru) | Ингибиторы mif | |
| CA2797767A1 (en) | Bicyclic compound derivatives and their use as acc inhibitors | |
| RU2010154400A (ru) | Гетероциклическое соединение | |
| RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
| EP3296309A8 (en) | Galactopyranosyl derivatives useful as medicaments | |
| EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
| WO2011056744A4 (en) | IRE-1 α INHIBITORS | |
| JP2009514801A5 (enExample) |